Comparison of Ertapenem and Ceftriaxone Therapy for Acute Pyelonephritis and Other Complicated Urinary Tract Infections in Korean Adults: A Randomized, Double-Blind, Multicenter Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Dae Won | - |
dc.contributor.author | Peck, Kyong Ran | - |
dc.contributor.author | Chung, Moon Hyun | - |
dc.contributor.author | Lee, Jin Seo | - |
dc.contributor.author | Park, Yoon Soo | - |
dc.contributor.author | Kim, Hyo Youl | - |
dc.contributor.author | Lee, Mi Suk | - |
dc.contributor.author | Kim, Jung Yeon | - |
dc.contributor.author | Yeom, Joon Sup | - |
dc.contributor.author | Kim, Min Ja | - |
dc.date.accessioned | 2021-09-06T20:10:34Z | - |
dc.date.available | 2021-09-06T20:10:34Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2012-05 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/108473 | - |
dc.description.abstract | The efficacy and safety of ertapenem, 1 g once daily, were compared with that of ceftriaxone, 2 g once daily, for the treatment of adults with acute pyelonephritis (APN) and complicated urinary tract infections (cUTIs) in a prospective, multicenter, double-blinded, randomized study. After >= 3 days of parenteral study therapy, patients could be switched to an oral agent. Of 271 patients who were initially stratified by APN (n = 210) or other cUTIs (n = 61), 66 (48.9%) in the ertapenem group and 71 (52.2%) in the ceftriaxone group were microbiologically evaluable. The mean duration of parenteral and total therapy, respectively, was 5.6 and 13.8 days for ertapenem and 5.8 and 13.8 days for ceftriaxone. The most common pathogen was Escherichia coli. At the primary efficacy endpoint 5-9 days after treatment, 58 (87.9%) patients in the ertapenem group and 63 (88.7%) in the ceftriaxone had a favorable microbiological response. When compared by stratum and severity, the outcomes in the two groups were equivalent. The frequency and severity of drug-related adverse events were generally similar in both treatment groups. The results indicate that ertapenem is highly effective and safe for the treatment of APN and cUTIs. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ACAD MEDICAL SCIENCES | - |
dc.subject | APPROPRIATE ORAL-THERAPY | - |
dc.subject | SOUTH-KOREA | - |
dc.subject | ENTEROBACTERIACEAE | - |
dc.subject | TOLERABILITY | - |
dc.subject | PREVALENCE | - |
dc.subject | GUIDELINES | - |
dc.subject | RESISTANT | - |
dc.subject | CYSTITIS | - |
dc.subject | SAFETY | - |
dc.title | Comparison of Ertapenem and Ceftriaxone Therapy for Acute Pyelonephritis and Other Complicated Urinary Tract Infections in Korean Adults: A Randomized, Double-Blind, Multicenter Trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Dae Won | - |
dc.contributor.affiliatedAuthor | Kim, Min Ja | - |
dc.identifier.doi | 10.3346/jkms.2012.27.5.476 | - |
dc.identifier.scopusid | 2-s2.0-84862898999 | - |
dc.identifier.wosid | 000303755600004 | - |
dc.identifier.bibliographicCitation | JOURNAL OF KOREAN MEDICAL SCIENCE, v.27, no.5, pp.476 - 483 | - |
dc.relation.isPartOf | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.citation.title | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.citation.volume | 27 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 476 | - |
dc.citation.endPage | 483 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001659969 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | APPROPRIATE ORAL-THERAPY | - |
dc.subject.keywordPlus | SOUTH-KOREA | - |
dc.subject.keywordPlus | ENTEROBACTERIACEAE | - |
dc.subject.keywordPlus | TOLERABILITY | - |
dc.subject.keywordPlus | PREVALENCE | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordPlus | RESISTANT | - |
dc.subject.keywordPlus | CYSTITIS | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordAuthor | Pyelonephritis | - |
dc.subject.keywordAuthor | Urinary Tract Infections | - |
dc.subject.keywordAuthor | Ertapenem | - |
dc.subject.keywordAuthor | Ceftriaxone | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.